These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Carroll C; Tappenden P; Rafia R; Hamilton J; Chambers D; Clowes M; Durrington P; Qureshi N; Wierzbicki AS Pharmacoeconomics; 2017 May; 35(5):537-547. PubMed ID: 28285379 [TBL] [Abstract][Full Text] [Related]
28. Reducing high blood cholesterol levels with drugs. JAMA; 1991 Apr; 265(15):1949-50. PubMed ID: 1901096 [No Abstract] [Full Text] [Related]
29. Simplifying the approach to the management of dyslipidemia. Gaziano JM; Gaziano TA JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241 [No Abstract] [Full Text] [Related]
30. [Treatment of high blood cholesterol in patients with coronary heart disease]. Nagai Y; Yanagi K; Yamashita S; Takemura K; Matsuzawa Y Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):1088-94. PubMed ID: 12436661 [No Abstract] [Full Text] [Related]
31. Poor adherence with hypolipidemic drugs: a lost opportunity. Tsuyuki RT; Bungard TJ Pharmacotherapy; 2001 May; 21(5):576-82. PubMed ID: 11349746 [TBL] [Abstract][Full Text] [Related]
32. An analysis of first authorizations for lipid-lowering drugs in Belgium. Devroey D; Betz W Acta Clin Belg; 2003; 58(3):152-8. PubMed ID: 12945474 [TBL] [Abstract][Full Text] [Related]
33. The ineffectiveness of a commonly recommended lipid-lowering diet in significantly lowering the serum total and low-density lipoprotein cholesterol levels. Roberts WC Am J Cardiol; 1994 Mar; 73(8):623-4. PubMed ID: 8147319 [No Abstract] [Full Text] [Related]
34. Reducing expenditures for statin-type lipid-lowering agents. Am J Health Syst Pharm; 1998 May; 55(10):995-6, 999. PubMed ID: 9606450 [No Abstract] [Full Text] [Related]
35. [A new approach to the treatment of dyslipidemia]. Kevelaitiene S; Slapikas R Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958 [TBL] [Abstract][Full Text] [Related]
36. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. McCrindle BW; Urbina EM; Dennison BA; Jacobson MS; Steinberger J; Rocchini AP; Hayman LL; Daniels SR; ; ; Circulation; 2007 Apr; 115(14):1948-67. PubMed ID: 17377073 [TBL] [Abstract][Full Text] [Related]
37. Guidelines for Clinical Evaluation, Development, and Regulation of Lipid-Acting Anti-Atherosclerosis Agents. Am J Cardiol; 1998 Apr; 81(8A):1F-94F. PubMed ID: 9634423 [No Abstract] [Full Text] [Related]
38. [Summary of the 'Cholesterol' guideline (first revision) of the Dutch College of Family Practice]. Bonneux L Ned Tijdschr Geneeskd; 2000 Apr; 144(18):862-3. PubMed ID: 10816777 [No Abstract] [Full Text] [Related]
39. The reply. Boyden TF Am J Med; 2015 Oct; 128(10):e75. PubMed ID: 26387006 [No Abstract] [Full Text] [Related]